---
phase: 216
reviewers: [codex]
reviewed_at: 2026-05-29
review_round: 2
review_target: 216-01-PLAN.md (executable plan review)
plans_reviewed: [216-01-PLAN.md]
note: "Round 1 (pre-plan CONTEXT.md framing review) archived at 216-REVIEWS-r1-context.md"
---

# Cross-AI Plan Review — Phase 216 (Round 2: executable plan)

> Round 1 reviewed the decision *framing* in CONTEXT.md (archived at
> `216-REVIEWS-r1-context.md`; its feedback was folded into CONTEXT + research).
> This round reviews the executable `216-01-PLAN.md`. Codex independently spot-checked the
> cited source/test surfaces and ran the focused test slice (`21 passed`).

## Codex Review

**Summary**

This plan is basically sound for a decision-only closeout. I spot-checked the cited source/test
surfaces and ran the focused slice: `21 passed`. The no-change / resolved-by-197 verdict is
defensible as long as the report keeps the narrow framing: Phase 197 tests prove the refractory
arbitration semantics; Phase 213 only proves no current observed symptom.

**Strengths**

- Clear phase boundary: no code, YAML, systemd, RouterOS, or tuning change.
- Correctly separates the evidence roles: 197 = semantic proof, 213 = absence-of-symptom only.
- Good task order: exit criteria → report → thread/STATE close.
- Reopen triggers are concrete and tied to `signal_arbitration.refractory_active`.
- The RECOV-03 caveat is present: no-change only, not evidence for future tuning.
- The focused test gate is appropriate for a closeout phase.

**Concerns**

- **MEDIUM:** The honesty gate is still partly grep-based. A report could contain the required
  strings and still overclaim elsewhere that 213 "validated" refractory behavior. Since the report
  is the deliverable, this is a real risk.
- **MEDIUM:** RECOV-03 is satisfied only by interpretation, not measurement. That is acceptable for
  no-change, but the report must not say "recovery lag measured" without the caveat. Better wording:
  "RECOV-03 gate not triggered because no tuning/change is approved."
- **MEDIUM:** The no-mutation gate is too narrow as written. `git diff --name-only` misses untracked
  files and allows accidental edits to tests/scripts/docs outside `src/`, `configs/`, `deploy/`, or
  YAML. For decision-only work, use an explicit changed-file allowlist.
- **LOW:** Plan frontmatter says `depends_on: []`, while roadmap says depends on Phase 213. Metadata
  should name Phase 213; 214/215 appear to be precedent/style references, not real blockers.
- **LOW:** D-04a mostly catches the right future failures, but it depends on refractory telemetry
  being present/correct. Add a fallback reopen trigger for the original symptom signature even if the
  refractory flag is absent or renamed.

**Suggestions**

- Add negative honesty checks / manual acceptance:
  - no unqualified "213 validated refractory semantics"
  - no "instant recovery" framing for `time_to_green_after_red_sec=0.0`
  - report must explicitly say "Phase 197 tests are the proof; Phase 213 shows no current symptom."
- Replace the diff gate with an allowlist using `git status --short --untracked-files=all`; expected
  changes should be only `216-EXIT-CRITERIA.md`, `216-REPORT.md`, the thread file, `STATE.md`, and the summary.
- Change plan metadata to `depends_on: [213]`.
- In reopen criteria, include "recurrence of the Phase 196 symptom signature: queue-delay signal
  present but `active_primary_signal == "rtt"` under queue-primary load, even if refractory telemetry
  is missing."
- Phrase RECOV-03 as a gate/waiver for no-change, not as completed transient recovery measurement.

**Risk Assessment**

**LOW**, assuming the suggestions above are applied or the executor reads the report manually. The
technical basis is strong, the phase does not touch runtime behavior, and the test evidence is
green. The main risk is editorial drift: closing a nuanced investigation with wording that sounds
stronger than the evidence.

---

## Consensus Summary

Single reviewer (Codex). Overall risk **LOW** — the plan is execution-ready; the concerns are
refinements that harden the deliverable against editorial drift and tighten the no-mutation guard.

### Agreed Strengths
- Decision-only boundary is clear and correctly scoped.
- Evidence roles correctly separated (197 = proof, 213 = no-symptom).
- Task sequencing and reopen triggers are sound.

### Agreed Concerns (highest priority first)
1. **(MEDIUM) Grep honesty gate is weak.** A report can pass string-presence checks and still
   overclaim. Add negative acceptance checks forbidding "213 validated" / "instant recovery" phrasing.
2. **(MEDIUM) No-mutation gate too narrow.** `git diff --name-only` misses untracked files. Switch
   to an allowlist via `git status --short --untracked-files=all` limited to the 5 expected artifacts.
3. **(MEDIUM) RECOV-03 wording.** Phrase as a gate/waiver ("not triggered — no change approved"),
   never "recovery lag measured."
4. **(LOW) `depends_on: []` should be `[213]`** to match the roadmap.
5. **(LOW) Reopen criteria fragility.** Add a refractory-telemetry-independent fallback: Phase 196
   symptom signature (queue-delay present but `active_primary_signal == "rtt"` under queue-primary load).

### Divergent Views
None (single reviewer).

### Recommended actions before execution
- **Plan edits (cheap, surgical):** set `depends_on: [213]`; replace the `git diff --name-only`
  acceptance gate with the `git status --untracked-files=all` allowlist; add the symptom-signature
  fallback to the D-04a reopen criteria.
- **Acceptance-criteria additions (Task 2):** negative honesty checks (no "213 validated", no
  "instant recovery"); RECOV-03 phrased as waiver/gate not measurement.
